With the announcement of yesterday's $350 million royalty agreement for Niktimvo with Royalty Pharma, we have strengthened our balance sheet significantly, and now have the capital to fund Syndax ...

Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...